valaciclovir + placebo

This entry refers to a combination used in clinical trials where one group receives valaciclovir (also known as valacyclovir) and the other receives a placebo. Valaciclovir is an oral antiviral medication, classified as a nucleoside analog DNA polymerase inhibitor, primarily used to treat infections caused by herpes viruses such as herpes simplex virus types 1 and 2 (causing genital herpes and cold sores), varicella zoster virus (causing shingles), and sometimes Epstein-Barr virus or cytomegalovirus. In the body, it is rapidly converted to acyclovir, which inhibits viral DNA synthesis by acting as a guanine nucleoside analog. Placebo is an inert substance with no pharmacological effect, included for comparison in randomized controlled trials[1][5][6]. This combination does not represent a marketed pharmaceutical product but rather describes the arms of clinical studies evaluating the efficacy of valaciclovir versus no active treatment.